Nino Rubino, MD
Family Medicine · Poland, OHNPI 1588649529
Payments from drug & device makers
Across 111 payments — averaging $12.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$238
- Merck$142
- AbbVie$138
- Amgen$128
- AstraZeneca$116
- Ironwood Pharmaceuticals, Inc$92
- plus $571 from 20 others
What the payments were for
- Food & beverage$1,41099%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $238 |
| Merck | 13 | $142 |
| AbbVie(2 entities) | 10 | $138 |
| Amgen | 8 | $128 |
| AstraZeneca | 8 | $116 |
| Ironwood Pharmaceuticals, Inc | 1 | $92 |
| Johnson & Johnson | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Amarin Pharma, Inc. | 5 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $67 |
| Novo Nordisk | 3 | $42 |
| Novartis | 2 | $38 |
| Boehringer Ingelheim | 2 | $23 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
| Promius Pharma LLC | 1 | $17 |
| Abbott | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $11 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| GSK | 1 | $11 |
How this compares
$1,424 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 380 | $308,732 |
| OzempicSemaglutide | 225 | $294,044 |
| JardianceEmpagliflozin | 163 | $149,864 |
| JanuviaSitagliptin Phosphate | 98 | $97,982 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 99 | $96,013 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $40,258 |
| TrulicityDulaglutide | 32 | $33,478 |
| XareltoRivaroxaban | 42 | $31,537 |
| EntrestoSacubitril/Valsartan | 24 | $27,278 |
| Spiriva RespimatTiotropium Bromide | 34 | $20,677 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $19,599 |
| MyrbetriqMirabegron | 17 | $18,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,419 |
| Repatha SyringeEvolocumab | 29 | $16,047 |
| TradjentaLinagliptin | 17 | $13,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $308,732380 claims |
| Novo NordiskOzempic | $42 | $294,044225 claims |
| MerckJanuvia, Janumet Xr, Janumet, Dulera | $142 | $219,878225 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $23 | $184,339214 claims |
| Johnson & JohnsonXarelto | $78 | $31,53742 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $11 | $30,14146 claims |
| NovartisEntresto | $38 | $27,27824 claims |
| AstraZenecaFarxiga, Symbicort | $116 | $18,78243 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $18,45717 claims |
| AbbVieSynthroid, Linzess | $138 | $14,036188 claims |
| Sanofi-aventis U.S. LLCMultaq | $11 | $11,45514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Poland
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.